In Vivo T Cell–Depleted Reduced-Intensity Conditioned Allogeneic HSCT for Patients With ALL in First Remission
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
Lancet Haematol 2022 Apr 01;9(4)e276-e288, DI Marks, L Clifton-Hadley, M Copland, J Hussain, TF Menne, A McMillan, AV Moorman, N Morley, D Okasha, B Patel, P Patrick, MN Potter, CJ Rowntree, AA Kirkwood, AK FieldingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.